Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10326MR)

This product GTTS-WQ10326MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10326MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15000MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ4681MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ10170MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ3548MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ5835MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ10637MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ8925MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ14945MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW